Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
 196 Products   52 Diseases   196 Products   3529 Trials   15381 News 


«12...157158159160161162163164165166167...208209»
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, Journal:  Efficacy of apatinib as third-line treatment of advanced colorectal cancer and prognostic analysis. (Pubmed Central) -  Mar 16, 2021   
    Apatinib is effective in the third-line treatment of advanced colorectal cancer, significantly improves the patient quality of life, and causes tolerable adverse reactions. The mPFS is markedly extended in the patients with CerB2++/+++, positivity rate of Ki-67 ≥50% and the presence of hypertension after treatment, which are the independent factors affecting the efficacy.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed, Trial completion date, Trial primary completion date:  CameL-sq: A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC (clinicaltrials.gov) -  Mar 15, 2021   
    P3,  N=390, Active, not recruiting, 
    The mPFS is markedly extended in the patients with CerB2++/+++, positivity rate of Ki-67 ≥50% and the presence of hypertension after treatment, which are the independent factors affecting the efficacy. Not yet recruiting --> Active, not recruiting | Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2021 --> Nov 2020
  • ||||||||||  retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
    Enrollment change, Trial primary completion date:  SHR-1701-I-103: SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Mar 12, 2021   
    P1,  N=120, Recruiting, 
    A high rate of AE-related dose reduction of apatinib could account for the observed differences. N=60 --> 120 | Trial primary completion date: Apr 2021 --> Apr 2022
  • ||||||||||  Herceptin (trastuzumab) / Roche
    [VIRTUAL] Immunotherapy directed to tumor antigen by multi-specific antibody () -  Mar 11, 2021 - Abstract #AACR2021AACR_3310;    
    In preliminary toxicology study, no animals in the dose exploration experiment showed abnormality in the body weight, body temperature, hematology examination etc in each dose group. Further studies are on-going to explore details of mechanism for efficacy toxicity and PK for this compound.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Clinical, Journal:  Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma. (Pubmed Central) -  Mar 4, 2021   
    Conclusion The combination therapy of apatinib plus S-1 was effective and well tolerated in the treatment of advanced ESCC patients after first-line chemotherapy failure. The combination therapy has the potential to be a potent therapeutic option for advanced ESCC patients after first-line chemotherapy failure.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Phase classification, IO biomarker:  Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 2, 2021   
    P2,  N=30, Recruiting, 
    The combination therapy has the potential to be a potent therapeutic option for advanced ESCC patients after first-line chemotherapy failure. Not yet recruiting --> Recruiting | Phase classification: P4 --> P2
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche
    Journal:  Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma. (Pubmed Central) -  Feb 27, 2021   
    The most common grade 3 or 4 toxicities were hypertension (5.8%), decreased appetite (5.8%), and thrombocytopenia (4.3%), most of which were resolved after symptomatic treatment or dose reduction. Apatinib plus temozolomide is an effective salvage regimen with manageable toxicities for recurrent glioblastoma and could not reduce the sensitivity to bevacizumab.
  • ||||||||||  AiRuiKa (camrelizumab) / Incyte
    [VIRTUAL] Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial (Channel 1) -  Feb 24, 2021 - Abstract #ELCC2021ELCC_47;    
    P3
    Consistently, confirmed ORR (64.8% [95% CI 57.6%–71.5%] vs 36.7% [95% CI 30.0%–43.9%], P < 0.0001) and DoR (median, 13.1 [95% CI 9.3–15.7] vs 4.4 [95% CI 4.2–4.9] months) per IRC favored the camrelizumab plus chemo group. Grade ≥3 treatment-related adverse events occurred in 73.6% of pts in the camrelizumab plus chemo group and 71.9% in the placebo plus chemo group, with no unexpected adverse effects.Conclusions The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceConclusions The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceptable safety profile, supporting this combination as an additional first-line treatment option for pts with advanced squamous NSCLC.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date:  A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) (clinicaltrials.gov) -  Feb 23, 2021   
    P2,  N=190, Active, not recruiting, 
    Grade ≥3 treatment-related adverse events occurred in 73.6% of pts in the camrelizumab plus chemo group and 71.9% in the placebo plus chemo group, with no unexpected adverse effects.Conclusions The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceConclusions The addition of camrelizumab to chemotherapy significantly prolonged PFS and OS in the first-line setting with an acceptable safety profile, supporting this combination as an additional first-line treatment option for pts with advanced squamous NSCLC. Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Feb 2020
  • ||||||||||  CS1002 (ipilimumab biosimilar) / CStone Pharma
    Trial completion, Enrollment change, Trial completion date:  A Phase I Study of CS1002 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Feb 21, 2021   
    P1,  N=6, Completed, 
    Active, not recruiting --> Completed | N=150 --> 105 Recruiting --> Completed | N=12 --> 6 | Trial completion date: May 2021 --> Sep 2020